NovaBay Pharmaceuticals (NYSEAMERICAN:NBY) Stock Price Down 1.6%

NovaBay Pharmaceuticals, Inc. (NYSEAMERICAN:NBY) shares fell 1.6% during trading on Monday . The company traded as low as $0.56 and last traded at $0.60, 2,566 shares changed hands during trading. A decline of 100% from the average session volume of 1,129,628 shares. The stock had previously closed at $0.61.

Separately, LADENBURG THALM/SH SH started coverage on shares of NovaBay Pharmaceuticals in a research note on Wednesday, September 18th. They set a “buy” rating and a $1.10 price target for the company.

The company’s fifty day moving average price is $0.68 and its two-hundred day moving average price is $1.02.

A hedge fund recently raised its stake in NovaBay Pharmaceuticals stock. Renaissance Technologies LLC lifted its stake in NovaBay Pharmaceuticals, Inc. (NYSEAMERICAN:NBY) by 1,283.0% in the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 412,469 shares of the biopharmaceutical company’s stock after purchasing an additional 382,645 shares during the period. Renaissance Technologies LLC owned 1.96% of NovaBay Pharmaceuticals worth $697,000 at the end of the most recent quarter.

About NovaBay Pharmaceuticals (NYSEAMERICAN:NBY)

NovaBay Pharmaceuticals, Inc, a biopharmaceutical company, develops, manufactures, and markets non-antibiotic and anti-infective products for the eye care market in the United States, China, and internationally. It offers Avenova, a prescription product for cleansing and removing foreign materials, including microorganisms and debris from skin around the eye; NeutroPhase for wound care market; CelleRx for the aesthetic dermatology market; Aganocide compounds patented synthetic molecules for use against bacteria, viruses, and fungi; auriclosene irrigation solution for urology; and intelli-Case, a device for soft and rigid gas permeable contact lenses.

Featured Story: The role of implied volatility with call option volume

Receive News & Ratings for NovaBay Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NovaBay Pharmaceuticals and related companies with's FREE daily email newsletter.


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on reddit